about
miR-137 inhibits proliferation of melanoma cells by targeting PAK2SEREX identification of new tumor antigens linked to melanoma-associated retinopathy.Serological analysis of human renal cell carcinoma.Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteins.Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.Estimating the activity of transcription factors by the effect on their target genesIdentification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice.Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy.SOX5 is involved in balanced MITF regulation in human melanoma cells.miR-339-3p Is a Tumor Suppressor in Melanoma.Generation of murine tumor cell lines deficient in MHC molecule surface expression using the CRISPR/Cas9 system.Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer.The role of microRNAs in melanoma.Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.LRAT overexpression diminishes intracellular levels of biologically active retinoids and reduces retinoid antitumor efficacy in the murine melanoma B16F10 cell line.Knockdown of lecithin retinol acyltransferase increases all-trans retinoic acid levels and restores retinoid sensitivity in malignant melanoma cells.Expression and activity of alcohol and aldehyde dehydrogenases in melanoma cells and in melanocytes.T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response.Autoantibodies against the Ca(2+)-binding protein recoverin in blood sera of patients with various oncological diseases.[Adoptive T-cell therapy of rhabdomyosarcoma].Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells.miR-137 inhibits melanoma cell proliferation through downregulation of GLO1.Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach.A vaccine targeting mutant IDH1 induces antitumour immunity.Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma.MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma.Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.miR-193b and miR-30c-1 inhibit, whereas miR-576-5p enhances melanoma cell invasionPrognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patientsCognate Interaction With CD4 T Cells Instructs Tumor-Associated Macrophages to Acquire M1-Like PhenotypePhotoreceptor proteins as cancer-retina antigensIdentification of HLA class I dependent immunogenic peptides from clonotypic TCRbeta expressed in cutaneous T-cell lymphomaCytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaTOptimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma modelsReprogramming of macrophages employing gene regulatory and metabolic network modelsMeasles Vaccines Designed for Enhanced CD8+ T Cell ActivationA transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic miceA universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival
P50
Q28265238-4C1C3839-9E8F-48BF-A01C-C195F6061EC6Q31124144-88BD4327-E79E-43EE-B0A6-CA4B70164296Q33228634-06C44C4C-3851-4177-A40C-756A6704D6CCQ33262863-9B4AC305-4411-4BD3-BA3C-98476261A228Q33770310-4B70A0D0-6CF0-42C6-99CF-29F1DE80A6F2Q33930161-D6DB490F-1D6B-4DA4-A552-18CF4D853B44Q34103144-A951A938-96B2-4844-B192-FE9F5553CE5CQ35411077-3896693C-38ED-431E-BAE4-D8330C5F2916Q35784865-5E8DEBD9-B717-4434-939C-48DC994629E8Q35939947-3B5A4EAD-91E6-475E-B0B2-2522F9E304FAQ36022856-2A42590C-1A3D-43B8-9034-5094BF6E8167Q36310789-3C07B22D-EEE3-4BBA-A081-9DA51C00CDBFQ36860418-AC3F1F6C-8992-42D9-813B-57A43F5D05FCQ38193922-BD737F60-FF56-4662-975F-2E4024B22783Q38734136-40F171EE-2371-44D2-96D7-FD283D0FABFDQ38905644-72A55A21-FA43-42C6-84FD-D407ACE34FC2Q38955200-40546046-8430-40F4-AD9E-F311F4B235A8Q39454052-5000C30D-DAE4-4126-8264-23C3CE95D188Q40752231-82B9A28C-5EED-41C4-8ACB-CD0D632D9F81Q42180602-968E4E0A-3C04-443A-8FA7-0591FEC7C4C5Q42929644-69834320-47AE-4DB8-86AB-B4AB49190DF2Q47112233-5208B427-E7E0-47EA-8518-3EE0DEF56402Q47196122-FFBF46D6-62C1-4447-8CC9-915656ED8C05Q48520172-8EA2A1DF-7D26-450C-898B-482A7816B2D3Q48649314-FFE52F95-E04B-4102-8CB1-F9FAA636AC55Q53072601-4EAB80FA-4268-41EF-A36E-6483A638BA58Q53201641-60EA3C80-9804-4120-8838-4FC3B11D5EC1Q55251496-B2269D70-65F7-4382-B9A4-0D1521FCF3C9Q57168333-81C5FBC2-4443-47E6-AF32-03DCD591D764Q58813659-A2F0E795-3413-4080-98E2-384D6B0D87A6Q64110647-1F78943C-AA9E-4451-B8C2-35CBE55C7C59Q79449841-F6577D55-25EF-42EE-88E9-7548625EDB51Q79956841-C684B969-01F2-4457-B498-0C74C1220B62Q81466175-C60B582E-009B-41F2-B86E-49E6533F86BAQ84975831-3D95E12E-9C52-4841-8219-6473D73AC6DCQ89097115-99921910-B732-42B3-A0B5-81FFE0FAD4BEQ89876255-5C80F90B-2461-4341-8B68-AE197C48161CQ89878795-BB58A227-6BD0-4D43-864D-722A3DC769C7Q90098354-134D9656-DF31-44CF-A484-C3E9D18ACDD4Q90937834-A8CEB684-41BC-4263-B229-5298C5647EBB
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stefan Eichmüller
@ast
Stefan Eichmüller
@bar
Stefan Eichmüller
@br
Stefan Eichmüller
@ca
Stefan Eichmüller
@ceb
Stefan Eichmüller
@co
Stefan Eichmüller
@da
Stefan Eichmüller
@de
Stefan Eichmüller
@en
Stefan Eichmüller
@es
type
label
Stefan Eichmüller
@ast
Stefan Eichmüller
@bar
Stefan Eichmüller
@br
Stefan Eichmüller
@ca
Stefan Eichmüller
@ceb
Stefan Eichmüller
@co
Stefan Eichmüller
@da
Stefan Eichmüller
@de
Stefan Eichmüller
@en
Stefan Eichmüller
@es
prefLabel
Stefan Eichmüller
@ast
Stefan Eichmüller
@bar
Stefan Eichmüller
@br
Stefan Eichmüller
@ca
Stefan Eichmüller
@ceb
Stefan Eichmüller
@co
Stefan Eichmüller
@da
Stefan Eichmüller
@de
Stefan Eichmüller
@en
Stefan Eichmüller
@es
P106
P21
P31
P496
0000-0002-3497-6904